Prescription Drug Monitoring Program: District of Columbia Profile

• NCJ Number: 252993
• Date Published: November 2018
• Length: 8 pages
• Sponsoring Agency: Bureau of Justice Assistance (BJA)
• Corporate Author: Brandeis University
• Sale Source: Bureau of Justice Assistance (BJA)
• Publication Format: Document; Document (Online)
• Publication Type: Report (Technical Assistance); Report (Summary); Report (Grant Sponsored); Program/Project Description; Legislative/Regulatory Material; Legislation/Policy Description
• Language: English
• Country: United States of America

Annotation

Comprehensive data and information are provided for the District of Columbia's Prescription Drug Monitoring Program (PDMP), named by the acronym DC PDMP.

Abstract

The administering agency is the Department of Health. The home PDMP website address is provided, and the extended website addresses are listed for enrollment and data upload. Contact information is provided for the Program Manager of Pharmaceutical Control. Statistics for 2017 cover the District of Columbia's population (703,608), DEA registered prescribers (9,603), and DEA registered dispensers (172). PDMP reports available are listed. Sources of funding for 2018 are reported to be licensing fees, the Regulatory Board fund, and Centers for Disease Control grant. Number of employees in various task categories are as follows: operational (2), technical (3), analytical (2), and "other" (0) , Key dates for the PDMP are for authorizing legislation (February 2014). date it became operational (August 2016), initial user access (October 2016), online access (October 2016), and when electronic reporting began (August 2016). Sources for relevant statutes and rules are reported, along with data reporting frequency (1 day). Drugs that require reporting are controlled substances under schedules II, III, IV, and V. The PDMP has the authority to monitor other substances and to remove substances from monitoring. Miscellaneous PDMP capabilities and policies are listed. There is no indication of required PDMP enrollment and use. Law enforcement agencies are required to report acrive drug investigations, including the citing of proper need for the investigation upon request. Requirements for data retention are set by policy, and all information is purged. No available training is reported as required before PDMP use. Information is provided on technological capabilities and requestors and reports authorized to generate and those being generated.